ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES

Abstract: A compound of formula (I) or the pharmaceutically acceptable salts thereof, wherein R<1> is (C1-C6)alkyl; R<2> is (C1-C6)alkyl; or R<1> and R<2> taken together with the carbon atom to which they are attached form a ring selected from (C5-C7)cycloalkyl, 4-tetrahydropyranyl and 4-piperidinyl; R<3> is hydrogen or (C1-C6)alkyl; and Y is a substituent of any of the carbon atoms of the phenyl ring capable of supporting an additional bond, preferably from 1 to 2 substituents (more preferably one substituent, most preferably one substituent in the 4-position) on the phenyl ring, independently selected from hydrogen, fluoro, chloro, trifluoromethyl, (C1-C6)alkoxy, trifluoromethoxy, difluoromethoxy and (C1-C6)alkyl.

Description: ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES Background of the Invention The present invention relates to aryloxyarylsulfonylamino hydroxamic acid derivatives These compounds are selective inhibitors of matπx metalloproteιnase-13 and as such are useful in the treatment of a condition selected from the group consisting of arthπtis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, bone resorption, loosening of artificial joint implants, atherosclerosis, multiple sclerosis, occular angiogenisis (for example macular degeneration) and other diseases characterized by matπx metalloproteinase activity This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans, and to the pharmaceutical compositions useful therefor There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metalloproteases atπx-degrading metalloproteinases, such as gelatinase, stromerysin and collagenase, are involved in tissue matπx degradation (e g collagen collapse) and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matπx metabolism, such as arthπtis (e g osteoarthntis and rheumatoid arthπtis), tissue ulceration (e g comeal, epidermal and gastπc ulceration), abnormal wound healing, peπodontal disease, bone disease (e g Paget's disease and osteoporosis) tumor metastasis or invasion, as well as HIV-infection (J Leuk Biol , 52 (2) 244-248 1992) Tumor necrosis factor is recognized to be involved in many infectious and auto-immune diseases (W Fners, FEBS Letters, 1991, 285 199) Furthermore, it has been shown that TNF is the pπme mediator of the inflammatory response seen in sepsis and septic shock (C E Spooner et al Clinical Immunology and Immunopathology, 1992, 62 S11) Summary of the Invention The present invention relates to a compound of the formula or the pharmaceutically acceptable salts thereof, wherein R 1 is (C,-C 6 )alkyl. R 2 is (C C 6 )alkyl, or R 1 and R 2 taken together with the carbon atom to which they are attached form a πng selected from (C 5 -C 7 )cycloalkyl 4-tetrahydropyranyl and 4-pιpeπdιnyl, R 3 is hydrogen or (C,-C 6 )alkyl, and Y is a substituent on any of the carbon atoms of the phenyl πng capable of supporting an additional bond, preferably from 1 to 2 substituents (more preferably one substituent most preferably one substituent in the 4-posιtjon) on the phenyl πng, independently selected from hydrogen, fluoro, chloro, tπfluoromethyl, (^-C^alkoxy tπfluoromethoxy, difluoromethoxy and (d-C^alkyl The term "alkyl", as used herein unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof The term "alkoxy", as used herein includes O-alkyl groups wherein "alkyl" is defined above The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, ι_e_, salts containing pharmacologically acceptable anions, such as the hydrochloπde, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, glucoπate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [u^, 1,1'-methylene-bιs-(2-hydroxy-3- naphthoate)]salts The invention also relates to base addition salts of formula I The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds Such non-toxic base salts include, but are not limited to those deπved from such pharmacologically acceptable cations such as alkali metal cations (e_g_ potassium and sodium) and alkaline earth metal cations (ejg_, calαum and magnesium), ammonium or water- soluble amine addition salts such as N-methylglucamιne-(meglumιne), and the lower alkanoiammonium and other base salts of pharmaceutically acceptable organic amines The compound of formula i may have chiral centers and therefore exist in different enantjomeπc forms This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof This invention also encompasses pharmaceutical compositions containing and methods of treating or preventing compπsing administeπng prodrugs of compounds of the formula I Compounds of formula I having free ammo, amido, hydroxy or carboxylic groups can be converted into prodrugs Prodrugs include compounds wherein an ammo acid residue, or a polypeptide chain of two or more (e g , two, three or four) ammo acid residues which are covalentjy joined through peptide bonds to free am o, hydroxy or carboxylic acid groups of compounds of formula I The ammo acid residues include the 20 naturally occumng ammo acids commonly designated by three letter symbols and also include, 4-hydroxyprolme, hydroxylysine, demosme, isodemosine, 3-methylhιsbdιne, norvalm, beta-alanine, gamma-aminobutyπc acid, αtrulline homocysteine, homoseπne, omrthme and methionine sulfone Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain Prodrugs also include compounds of formula I in which the hydroxamic acid and carbonyl moiety when taken together form a group of the formula wherein R 1 , R 2 and Y are as defined in formula I and U and V are independently carbonyl, methylene, S0 2 or S0 3 , and b is an integer from one to three wherein each methylene group is optionally substituted with hydroxy Preferred compounds of formula I include those wherein Y is hydrogen, fluoro or chloro, preferably 4-fiuoro or 4-chioro Other preferred compounds of formula I include those wherein R 1 and R 2 taken together with the carbon atom to which they are attached form a cyclopentyl or 4-tetrahydropyranyl πng Other preferred compounds of formula I include those wherein R 1 and R 2 are both methyl Other preferred compounds of fomnula I include those wherein R 3 is hydrogen Specific preferred compounds of formula I include the following 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclopentyl)amιno]- propionic acid ethyl ester, 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclopentyl) amιno]propιonιc acid, 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1 -hydroxy carbamoyl-1- methylethyl)amιno]propιonιc acid ethyl ester, and 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoyl-1- methylethyl)amιno]propιonιc acid Other compounds of formula I include the following 3-[[4-(4-fiuorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoyltetrahydropyran-4-yl)- amιno]propιonιc acid, 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoyltetrahydropyran-4-yl)- amino j propionic acid ethyl ester, 3-[[4-(4-chlorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoyltetrahydropyran-4-yl)- aminojpropiomc acid, 3-[[4-(4-chlorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoyltetrahydropyran-4-yI)- amιno]proptonιc acid ethyl ester, 3-[(4-hydroxycarbamoyltetrahydropyran- -yl)-(4-phenoxybenzenesulfonyl)amιno}- propionic acid. 3-[(4-hydroxycarbamoyltetrahydropyran-4-yl)-(4-phenoxybenzenesulfonyl)amιno]- propionic acid ethyl ester, 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoylpιpeπdιn-4-yl)- aminojpropionic acid ethyl ester, 3-[[4.(4^hlorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyl-1-methylethyl)amιno3- propionic acid, 3-[[4-{4-chlorophenoxy)be nzenesulfonyl]-(1 -hydroxy carbamoyl-1 -methylethyl)amιno]- propionic acid ethyl ester, 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-( 1 -hydroxycarbamoylcyclohexyl)amino]- propionic acid, 3-[(1-hydroxycarbamoylcyclopentyl)-(4-phenoxybenzenesulfonyl)amιno]propιonic acid, and 3-[[4-(4-chlorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyicyclopentyi)amino]- propionic acid. The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, peπodontal disease, epidermolysis bullosa, bone resorption, loosening of artificial joint implants, atherosclerosis, multiple sclerosis, occular angiogenisis (for example macular degeneration) and other diseases characteπzed by matπx metalloproteinase activity, or (b) the selective inhibition of matπx metalloproteιnase-13 in a mammal, including a human, compπsing an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in such treatments and a pharmaceutically acceptable carrier. The present invention also relates to a method for the selective inhibition of matπx metalloproteιnase-13 or in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for treating a condition selected from the group consisting of arthπtis, cancer, tissue ulceration, restenosis, peπodontal disease, epidermolysis bullosa, bone resorption, loosening of artificial joint implants, atherosclerosis, multiple sclerosis, occular angiogenisis (for example macular degeneration) and other diseases characteπzed by matπx metalloproteιnase-13 activity in a mammal, including a human, compπsing administering to said mammal an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in treating such a condition. Detailed Description of the Invention The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated Y, R 1 , R 2 and R 3 in the reaction Schemes and the discussion that follow are defined as above. Scheme 1 VII IV Scheme 1 Cont'd IV Scheme 1 refers to the preparation of compounds of the formula I from compounds of the formula VII Referπng to Scheme 1, the am o acid compound of formula VII, wherein R 16 is benzyl, is converted to the corresponding compound of formula VI by reaction with a reactive functional deπvative of an arylsulfonic acid compound of the formula VIII in the presence of a base, such as tπethylamine, and a polar solvent, such as tetrahydrofuran, 1 ,2-dιmethoxyethane, dioxane, water or acetonitπle, preferably 1 ,2- dimethoxyethane The reaction mixture is stirred, at room temperature, for a time period between about 10 minutes to about 24 hours, preferably about 60 minutes The arylsulfonylamino compound of formula VI, wherein R 16 is benzyl, is converted to the corresponding compound of formula V, wherein R 18 is the group 3-tert-butyl- dimethylsilanyloxypropanyl by reaction with tert-butyl-(3-halo-propoxy)dιmethylsιlane, preferably the iodide deπvative, in the presence of a base, such as potassium carbonate, cesium carbonate, potassium hexamethyldisilazide, or sodium hydnde, preferably potassium hexamethyldisiiazide The reaction is stirred in a polar solvent, such as dimethyrformamide or N- methylpyrrolιdιn-2-one at room temperature, for a time peπod between about 2 hours to about 48 hours, preferably about 18 hours The compound of formula V is converted to a carboxylic acid deπvative of formula IV by reaction with boron tπfiuoπde-etherate complex to form an intermediate alcohol, followed by oxidation and protection by esteπfication Specifically, the reaction with boron tπfiuoπde-etherate complex is performed in an inert solvent such as methylene chloπde, chloroform, preferably methylene chloπde, at room temperature for about 15 minutes to about 4 hours, preferably about one hour Oxidation of the alcohol is facilitated by using chromium tπoxide in aqueous sulfuπc acid (Jones Reagent) at about 0°C for about one to about 6 hours, preferably about 2 hours Protection of the carboxylic aαd is facilitated by treatment of the free acid with an alkylating agent such as R 3 -L, wherein L is a leaving group such as iσdo, bromo, mesylate, or tosylate, preferably KXJO, with a base, such potassium carbonate or cesium carbonate, preferably potassium carbonate, in a polar solvent such as dimethyrformamide, N-methylpyrrolιdιn-2-one or tetrahydrofuran, preferably dimethyl formamide, for about 1 to about 24 hours, preferably 16 hours, at about room temperature The compound of formula IV is converted to a compound of formula III by removal of the R 1ε protecting group by hydrogenolysis using palladium on carbon in a solvent such as methanol or ethanol, for a peπod from about 30 minutes to about 48 hours, preferably 16 hours, at a temperature of about 20°C to about 25°C, i e room temperature The carboxylic acid compound of formula III is converted to the hydroxamic acid deπvative of formula II, wherein R 16 is benzyl, by activation of the compound of formula 111 followed by reaction with benzylhydroxylamine The compound of formula III is activated by treatment with (benzotrιazol-l-yloxy)tπs(dιmethylamιno) phosphonium hexafiuorophosphate in the presence of a base, at room temperature, in a polar solvent The aforesaid reaction is conducted for a peπod of about 15 minutes to about 4 hours, preferably about 1 hour. T e activated compound deπved from formula III is converted in situ to the compound of fomnula II by reaction with benzylhydroxylamine hydrochloπde The reaction with benzylhydroxylamine hydrochloπde is conducted for about 1 hour to about 5 days, preferably for about 16 hours, at a temperature of about 40°C to about 80°C, preferably about 60°C Suitable bases include N- methylmorphoiine or dnsopropylethylamine, preferably dusopropylethylamine Suitable solvents include N,N-dιmethylformamιde or N-methylpyσoiιdιn-2-one, preferably N,N-dιmethylformamιde The compound of fomnula II is converted into a compound I by removal of the hydroxy I amme protecting group Removal of the hydroxyiamme protecting group is earned out by hydrogenolysis of the benzyl protecting group using catalytic palladium on baπum sutfate in a polar solvent at a temperature from about 20°C to about 25°C, i e room temperature, for a peπod of about I hour to about 5 hours, preferably about 3 hours Compounds of formula VII and VIII are commercially available or can be made by methods well known to those of ordinary skill in the art. Pharmaceutically acceptable salts of the acidic compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, caiαum, magnesium, as well as ammonium salts, such as ammonium, tπmethyl-ammonium, diethylammonium, and tπs-(hydroxymethyl)-methylammonιum slats Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids e g hydrochlonc acid, methanesulfonic acid maleic acid, are also possible provided a basic group, such as pyπdyl, constitutes part of the structure The compounds of the formula I which are basic in nature are capable of forming a wide vaπety of different salts with vaπous inorganic and organic acids Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the free base to a pharmaceutically acceptable acid addition salt The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol Upon careful evaporation of the solvent, the desired solid salt is obtained The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, _ \ _, salts containing pharmacologically acceptable anions, such as hydrochloπde, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate succiπate, maleate, fumarate glucoπate saccharate benzoate, methanesulfonate and pamoate [i e , 1 ,1'-methylene-bιs-(2-hydroxy-3- naphthoate)] salts Those compounds of the formula I which are also acidic in nature, e j_, where R 3 is hydrogen, are capable of forming base salts with vaπous pharmacologically acceptable cations Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts These salts are all prepared by conventional techniques The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein descπbed acidic compounds of formula I These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure Alternatively, they may also be prepared by mixing lower alkano c solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before In either case, stoichiometπc quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields The ability of the compounds of fomnula I or their pharmaceutically acceptable salts (hereinafter also referred to as the MMP-13 selective compounds of the present invention) to inhibit matπx metalloproteιnase-13 (collagenase 3) and, consequently, demonstrate their effectiveness for treating diseases characteπzed by matπx metalloproteιnase-13 is shown by the following in vitro assay tests Biological Assay Inhibition of Human Collagenase ( MP-1) Human recombinant collagenase is activated with trypsin using the following ratio 10 mg trypsin per 100 mg of collagenase The trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 mg/10 mg trypsin) of soybean trypsin inhibitor is added 10 mM stock solutions of inhibitors are made up in dimethyl suifoxide and then diluted using the following Scheme 10 mM > 120 uM > 12 μM > 1 2 μM > 0 12 μM Twenty-five microliters of each concentration is then added in tπplicate to appropπate wells of a 96 well microfluor plate The final concentration of inhibitor will be a 1 4 dilution after addition of enzyme and substrate Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells D7-D12 Coliagenase is diluted to 400 ng ml and 25 ml is then added to appropπate wells of the microfluor plate Final concentration of collagenase in the assay is 100 ng/ml Substrate (DNP-Pro-Cha-Gly-Cys(Me)-Hιs-AIa-Lys(N )-NH 2 ) is made as a 5 mM stock in dimethyl suifoxide and then diluted to 20 mM in assay buffer The assay is initiated by the addition of 50 ml substrate per well of the microfluor plate to give a final concentration of 10 mM Fluorescence readings (360 nM excitation 460 nm emission) were taken at time 0 and then at 20 minute intervals The assay is conducted at room temperature with a typical assay time of 3 hours Fluorescence vs time is then plotted for both the blank and collagenase containing samples (data from triplicate determinations is averaged) A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine IC 50 values The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data Data is plotted as inhibitor concentration vs % control (inhibitor fluorescence divided by fluorescence of collagenase alone x 100) IC^'s are determined from the concentration of inhibitor that gives a signal that is 50% of the control If ICso's are reported to be <003 mM then tine inhibitors are assayed at concentrations of 0 3 mM, 0 03 mM, 0 03 mM and 0 003 mM Inhibition of MMP-13 Human recombinant MMP-13 is activated with 2mM APMA (p-ammophenyl mercuπc acetate) for 1 5 hours, at 37 β C and is diluted to 400 mg/ml in assay buffer (50 mM Tπs, pH 7 5, 200 mM sodium chloπde, 5mM calαum chloπde, 20mM zinc chloride, 0 02% bπj) Twenty-five microliters of diluted enzyme is added per well of a 96 well microfluor plate The enzyme is then diluted in a 1 4 rabo in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml 10 mM stock solutions of inhibitors are made up in dimethyl suifoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1) Twenty-five microliters of each concentration is added in tπplicate to the microfluor plate The final concentrations in the assay are 30 mM, 3mM, 0 3 mM, and 0 03 mM Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-Hιs-Ala-Lys(NMA)-NH 2 ) is prepared as for inhibition of human collagenase (MMP-1) and 50 ml is added to each well to give a final assay concentration of 10 mM Fluorescence readings (360 nM excitation, 450 emission) are taken at time 0 and every 5 minutes for 1 hour Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only ICso's are determined as per inhibition of human collagenase (MMP-1) If ICso's are reported to be less than 0 03 mM, inhibitors are then assayed at final concentrations of 0 3 mM, 0 03 mM, 0 003 mM and 0 0003 mM The compounds of the present invention possess surpπsingly selective activity against matπx metalloproteιnase-13 (collagenase 3) as compared to matrix metalloproteιnase-1 (collagenase 1) Specifically, the compounds of the fomnula I are 100 times more selective for matπx metalloproteinase- 13 (collagenase 3) than matπx metalloproteinase- 1 (collagenase 1 ) and have ICso s of less than 10nM against matrix metalloproteιnase-13 (collagenase 3) Table 1 lists several compounds that demonstrate the unexpected selectivity of the compounds of the invention TABLE 1 For administration to humans for the inhibition of matrix metalioproteinase-13 or the production of tumor necrosis factor (TNF), a variety of conventional routes may be used including orally, parenterally and topically. In general, the active compound will be administered orally or parenterally at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject T e compounds of the present invention can be administered in a wide vaπety of different dosage forms, in general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5 0% to about 70% by weight For oral administration, tablets containing vaπous excipients such as microcrystalline cellulose sodium citrate, calcium carbonate, dicalcium phosphate and gtycme may be employed along with vanous disintegrants such as starch (and preferably com potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like potyvinylpyrrolidone sucrose, gelation and acacia Additionally, lubncating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes Solid compositions of a similar type may also be employed as fillers in gelatin capsules, preferred mateπals in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols When aqueous suspensions and or ehxirs are desired for oral administration, the active ingredient may be combined with vaπous sweetening or flavoπng agents, coloπng matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene gtycol, glyceπn and vaπous like combinations thereof For parenteral administration (intramuscular, trapeπtoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic These aqueous solutions are suitable intravenous injection purposes The oily solutions are suitable for intraar cular, intramuscular and subcutaneous injection purposes The preparation of all these solutions under steπle conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the ar The following Examples illustrate the preparation of the compounds of the present invention Melting points are uncorrected NMR data are reported in parts per million (δ) and are referenced to the deuteπum lock signal from the sample solvent (deuteπodimethylsulfoxide unless otherwise specified) Commercial reagents were utilized without further purification THF refers to tetrahydrofuran DMF refers to N,N-dιmethylformamιde Chromatography refers to column chromatography performed using 32-63 mm silica gel and executed under nitrogen pressure (flash chromatography) conditions Room or ambient temperature refers to 20 to 25°C All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields Concentration at reduced pressure means that a rotary evaporator was used Example 1 3-[[4.(4-FLUOROPHENOXY)BENZENESULFONYL]-(1-HYDROXY-CARBAMOYL CYCLOPENTYL)AMINO]-PROPIONlC ACID ETHYL ESTER (A) To a solution of 1-amιnocyclopentanecarboxylιc acid benzyl ester p- toluenesulfonic acid salt (200 grams, 0 51 mole) and tinethylamine (177 mL, 1 27 mole) in water (1 L) and 1 ,2-dιmethoxyethane (1 L) was added 4-(4-fiuorophenoxy)benzenesulfonyl- chloπde (161 grams, 0 56 moles) The mixture was stirred at room temperature for 16 hours and then most of the solvent was removed by evaporation under vacuum The mixture was diluted with ethyl acetate and was washed successively with dilute hydrochloπc acid solution, water, and bπne The solution was dπed over magnesium sulfate and concentrated to leave a brown solid Tπturation with diethyl ether to afforded 1-[4-(4- fluorophenoxy)benzenesulfonylammo]-cyclopentanecarboxylic acid benzyl ester as a tan solid, 167 grams (70%) (B) To a solution of 1-[4-(4-fluorophenoxy)benzenesulfonylamιno]- cyclopentanecarboxylic acid benzyl ester (199 grams, 0 42 mole) in dry N,N- dimethylformamide (2 5 L) at room temperature was added potassium hexamethyldisilazide (100 grams, 0 50 mole) and after 3 hours, tert-buty!-(3-ιodopropoxy)dιmethylsιlane (150 grams, 0 50 mole) The resulting mixture was stirred at room temperature for 16 hours Additional tert-butyl-(3-ιodopropoxy)-dιmethytsιlane (20 grams 0 067 mole) was then added Stirring at room temperature was continued for a further 3 5 hours The mixture was quenched by addition of saturated ammonium chloπde solution The N,N-dιmethylformamιde was removed by evaporation under vacuum The residue was taken up in diethyl ether and washed with water and brine After drying over magnesium sulfate, the diethyl ether was evaporated to afford crude 1-{[3-(tert-butyl-dιmethylsιlanyloxy)-propyl]-[4-(4- fluorophenoxy)benzenesulfonyl]-amιno}cyciopentanecarboxylιc acid benzyl ester as an amber oil (279 6 grams) (C) To a solution of the crude 1-{[3-(tert-butyl-dιmethylsιlanyioxy)-propyl]-[4-(4- fluorophenoxy)benzenesulfonyl]-amιno}cyclopentanecarboxylιc acid benzyl ester (279 grams) in methylene chloπde (1 L) at room temperature was added boron tπfluoπde etherate (103 mL, 0 84 mole) After 1 hour, the reaction was quenched by sequential addition of saturated ammonium chloride solution and water The organic phase was separated, washed with water and bπne and dπed over magnesium sulfate Evaporation of the solvent under vacuum provided crude 1-[[4-(4-fluorophenoxy)benzenesulfonyl]-(3-hydroxypropyl)amino] cyclopentanecarboxylic acid benzyl ester as an amber oil (235 grams). (D) A solution of the crude 1-[[4-(4-fluorophenoxy)benzenesulfonyl]-(3- hydroxypropyl)amino]cycJopentanecarboxylic acid benzyl ester (235 grams) in acetone (2 L) was cooled in an ice bath and treated with Jones reagent (about 200 mL) until an orange color persisted. The mixture was stirred from 0°C to room temperature over 1 hour. After quenching excess oxidaπt with isopropanol (10 mL), the mixture was filtered and the filtrate was concentrated under vacuum. The residue was taken up in ethyl acetate, washed with water and brine, dried over magnesium sulfate and concentrated to afford a solid which was triturated with a mixture of diethyl ether and hexane to provide 1-{(2-carboxyethyl)-[4-(4- fluorophenoxy)benzenesulfony!]amino}cyclopentane carboxylic acid benzyl ester as a white solid, (147 grams). (E) To a solution of 1-{(2-carboxyethyl)-[4-(4-fluorophenoxy)benzenesulfonyl] amino}- cyclopentanecarboxyiic acid benzyl ester (147 grams) in N,N-dimethyl formamide (3 L) at room temperature was added potassium carbonate (150 grams, 1.08 mole) and ethyl iodide (32.4 mL, 0.405 mole). The mixture was stirred for 16 hours at room temperature. After filtration, most of the solvent was removed under vacuum. The residue was taken up in water and acidified using 6N aqueous hydrogen chloride solution. The resulting mixture was extracted with diethyl ether. The organic extract was washed with water and brine, dried over magnesium sulfate, and concentrated to yield 1-{(2-ethoxycarbonylethyl)-[4-(4- fluorophenoxy)benzenesulfonyi] amino}cyclopentane carboxylic acid benzyl ester as a yellow semi-solid (149.1 grams, 96%). (F) A solution of 1-{(2-ethoxycarbonylethyl)-[4-(4-fluorophenoxy)benzene sulfonyl]- amino}cyclopentanecarboxylic acid benzyl ester (74.5 grams, 0.13 mole) in ethanol (1.8 L) was treated with 10% palladium on activated carbon (7.4 grams) and hydrogenated in a Parr™ shaker at 3 atmospheres pressure for 16 hours. After filtration through nylon (pore size 0.45 μm) to remove the catalyst, the solvent was evaporated to afford H(2- ethoxycarbonylethyl)-[4-(4-fiuorophenoxy)beπzenεsutfonyl]amino} cyclopentanecarboxylic acid as a white foam. The reaction was repeated on the same scale to provide, in total, 125.2 grams of the desired product. (G) Diisopropylethylamine (50 mL, 0.286 mole) and (benzotriazol-l-yloxy)tris- (dimethylamino)phosphonium hexafluorophosphate (126.5 grams, 0.286 mole) were added sequentially to a solution of 1-{(2-ethoxycarbonylethylH4-(4-fluorophenoxy)benzene- sulfonyl]amino}cyclopentanecarboxylic acid (125.2 grams, 0.26 mole) in N,N- dimethyiformamide (2 L). The mixture was stirred for 1 hour. Additional diisopropylet ylamine (91 mL, 0.52 mole) and 0-benzylhydroxylamine hydrochloride (53.8 grams, 0 338 mole) were then added and the resulting mixture was stirred at 60°C for 96 hours After concentration under vacuum, the resiαue was taken up in water and acidified with 1 N aqueous hydrogen chloride solution The mixture was extracted with ethyl acetate and the extract was washed sequentially with water, saturated aqueous sodium bicarbonate solution and brine The solution was dried over magnesium sulfate and concentrated to give crude 3-{(1-benzyloxycarbamoylcyclopentyl)-[4-(4-fiuorophenoxy)benzenesulfonyl]- amιno}propιonιc acid ethyl ester as a yellow oil (164 grams). F) A solution of crude 3-{(1-benzyloxycarbamoylcyclopeπtyl)-[4-(4-fiuorophenoxy)- benzenesulfonyl]amιno}propιonιc acid ethyl ester (164 grams) in ethanol (2 4 L) was treated with 5% palladium on barium sulfate (50 grams) and hydrogenated in a Parr™ shaker at 3 atmospheres pressure for 3 hours After filtration through nylon (pore size 0 45 μm) to remove the catalyst, the solvent was evaporated to afford an oil After addition of ethyl acetate and hexane, 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy- carbamoylcyclopeπtyl)amιno]-propιonιc acid ethyl ester, a white crystalline solid (73 5 grams) was collected by filtration The filtrate was concentrated and the residue was chromatographed on silica gel eluting with 40% ethyl acetate hexane to provide more of the desired product (32 5 grams) Mp 79-83°C 1 H NMR (DMSO-dβ) δ 10 40 (br s, 1 H), 8 78 (br s, 1 H), 7 80-7 77 (m, 2 H), 7 31-7 03 (m, 6 H), 4 02 (q, J = 7 3 Hz, 2 H), 3 49-3 45 (m, 2 H), 2 70-2 67 (m, 2 H), 2 24-2 21 (m. 2 H), 1 86-1 83 (m, 2 H), 1 53-1 50 (m, 4 H), 1 16 (t, J = 7 3 Hz, 3 H) MS 493 (M-1 ) Analysis calculated for C23H27F 2O7S H 2 0 C, 53 90, H, 5 70, N 5 47 Found C, 54 52, H 5 63, N 5 27 Example 2 3.[[4-(4-FLUOROPHENOXY)BENZENESULFONYL1-(1-HYDROXY- CARBAMOYLCYCLOPENTYL) AMINO]PROPIONIC ACID A solution of 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyl cyclopentyl)-amιno]propιonιc acid ethyl ester (106 grams, 0 214 mole) in ethanol (2 5 L) was treated with aqueous 1 N sodium hydroxide solution (856 mL, 0 856 mole) and stirred at room temperature for 2 hours The mixture was concentrated to remove ethanol, diluted with water, acidified with 6 N aqueous hydrochloπc acid solution and extracted with ethyl acetate After washing with water and bπne, the organic extract was dπed over magnesium sulfate and concentrated to a foam Crystallization from 30% ethyl acetate in hexane gave 3-[[4-(4- fluorophenoxy)benzenesulfonyl]-(1 -hydroxy carbamoylcyclopentyl)-amιno]propιonιc acid as a white crystalline solid (81 5 grams 81%) Mp 170-172°C 1 H NMR (DMSO-dβ) δ 12 25 (br s, 1 H), 10 40 (br s, 1 H), 8 74 (br s, 1 H), 7 79-7 77 (m, 2 H), 7 29-7 03 (m, 6 H), 3 45-3 41 (m, 2 H), 2 61-2 57 (m, 2 H), 2 24- 2 21 (m, 2 H), 1 88-1 82 (m, 2 H), 1 53-1 50 (m, 4 H) MS 465 (M-1) Analysis calculated for C21 H23FN2O7S C, 54 07, H, 4 97 N, 6 00 Found C, 54 17, H 5 02, N, 6 05 Example 3 3-f [4.(4.FLUOROPHENOXY)BENZENESULFONYLH1 -HYDROXYCARBAMOYL-1 - METHYLETHYDAMINOIPROPIONIC ACID ETHYL ESTER The title compound was prepared according to a procedure analogous to that outlined in Example 1 starting with 2-amιno-2-methyl-propιonιc acid benzyl ester p-toluenesulfonic acid salt Mp 124 8-125° C 1 H NMR (DMSO-dδ) δ 10 37 (s, 1 H), 8 74 (s,1 H), 7 86 (d, 2 H, J = 8 9 Hz), 7 16-7 30 (m, 4 H), 7 04 (d, 2 H, J = 8 7 hz), 3 99 (q, 2 H, J = 7 1 Hz), 3 33-3 37 (m, 2 H) 2 62-2 66 (m, 2 H), 1 40 (s, 6 H), 1 13 (t, 3 H, J = 7 1 Hz) MS 467 (M-1) Analysis calculated for C21H25FN2O7S C, 53 84, H, 5 38, N, 5 98 Found C, 54 00, H, 5 12, N, 5 87 Example 4 3-rr4-(4-FLUOROPHENOXY)BENZENESULFONYLH1-HYDROXY- CARBAMOYL-1 -METHYLETHYL)AMIN01PROPIONIC ACID The title compound was prepared from 3-{J4-(4-fiuorophenoxy)benzenesulfonyl]-(1- hydroxycarbamoyl-1-methyiethyl)arnino]propionic acid ethyl ester according to a procedure analogous to that described in Example 2. Mp: 162-162.5°C. MS: 439 (M-1 ). 1 H NMR (DMSO-d6) δ 12.26 (s, 1 H) 10.10.38 (s, 1 H), 8.75 (s,1 H), 7.86-7.88 (m, 2 H). 7.16-7.7.30 (m, 4 H), 7.03-7.06 (m, 2 H), 3.29-3.35 (m, 2 H), 2.47-2.59 (m, 2 H), 1.40 (s. 6 H).

Claims: CLΛIMS A compound of the formula or the pharmaceutically acceptable salts thereof, wherein R 1 is (C C 6 )alkyl, R 2 is (C r C ε )alkyl, or R 1 and R 2 taken together with the carbon atom to which they are attached form a πng selected from (C 3 -C 7 )cycloalkyl , 4-tetrahydropyranyl and 4-pιpeπdιnyl, R 3 is hydrogen or (C C 6 )alkyl, and Y is a substituent on any of the carbon atoms of the phenyl πng capable of supporting an additional bond, independently selected from fluoro, chloro, tπfluoromethyl (C ^sJalko y tπfluoromethoxy difluoromethoxy and (C^eJalkyl 2 A compound according to claim 1 wherein Y is hydrogen, fluoro or chloro 3 A compound according to claim 1 wherein Y is 4-fluoro or 4-chloro 4 A compound according to claim 1, wherein R 1 and R 2 taken together with the carbon atom to which they are attached form a cyclopentyl πng 5 A compound according to claim 3, wherein R 1 and R 2 taken together with the carbon atom to which they are attached form a cyclopentyl πng 6 A compound according to claim 1 , wherein R ' and R 2 taken together with the carbon atom to which they are attached form a 4-tetrahydropyranyl πng 7 A compound according to claim 1 , wherein R 1 and R 2 are both methyl 8 A compound according to claim 3, wherein R 1 and R 2 are both methyl 9 A compound according to claim 1 wherein R 3 is hydrogen 10 A compound according to claim 3, wherein R 3 is hydrogen 11 A compound according to claim 4, wherein R 3 is hydrogen 12 A compound according to claim 1, wherein said compound is selected from the group consisting of 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclopentyl)amιno]- propionic acid ethyl ester, 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclopentyl) amιno]propιonιc acid, 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyl-1- methylethyl)amιno]propιonιc acid ethyl ester, and 3-[[4-{4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoyl-1- methylethyl)amιno]propιonιc acid 13 A pharmaceutical composition for (a) the treatment of arthπtis or cancer and other diseases characteπzed by matπx metalloproteιnase-13 activity or (b) the selective inhibition of matπx metalloproteιnase-13 in a mammal, including a human, compπsing an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in such treatments or inhibition and a pharmaceutically acceptable earner 14 A method for the selective inhibition of matinx metalloproteιnases-13 in a mammal, including a human, compπsing admiπisteπng to said mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof 15 A method for treating arthπtis or cancer and other diseases characteπzed by matπx metalloproteιnase-13 activity in a mammal, including a human, compπsing administeπng to said mammal an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof effective in treating such a condition

Inventors: ROBINSON RALPH PELTON, ROBINSON, RALPH, PELTON
Applicants: PFIZER PROD INC, ROBINSON RALPH PELTON, PFIZER PRODUCTS INC., ROBINSON, RALPH, PELTON
Application year: 1998
Main classification: C07C311
IPC codes: A61K31, A61P35, C07C311, C07D211, C07D309